

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

**Complete if Known**

Application Number	10/560,653
Filing Date	November 20, 2006
First Named Inventor	David B. Weiner
Art Unit	1648
Examiner Name	Bao Q. Li
Attorney Docket Number	130694.02201

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	AA	US-4,722,848	02-02-1988	Paoletti, et al.	
	AB	US-4,945,050	07-31-1990	Sanford, et al.	
	AC	US-5,017,487	05-21-1991	Stunnenberg, et al.	
	AD	US-5,036,006	07-30-1991	John C. Sanford, et al.	
	AE	US-5,077,044	12-31-1991	Bruce Arnold D. Stocker	
	AF	US-5,110,587	05-05-1992	Enzo Paoletti	
	AG	US-5,112,749	05-12-1992	Robert N. Brey	
	AH	US-5,174,993	12-29-1992	Enzo Paoletti	
	AI	US-5,223,424	06-29-1993	Mark D. Cochran	
	AJ	US-5,225,335	07-06-1993	Enzo Paoletti	
	AK	US-5,240,703	08-31-1993	Mark D. Cochran	
	AL	US-5,242,829	09-07-1993	Dennis L. Panicali	
	AM	US-5,294,441	03-15-1994	Roy Curtiss	
	AN	US-5,294,548	03-15-1994	James H. McInden	
	AO	US-5,310,668	05-10-1994	Ronald W. Ellis	
	AP	US-5,387,744	02-07-1995	Roy Curtiss	
	AQ	US-5,389,368	02-14-1995	Roy Curtiss	
	AR	US-5,424,065	06-13-1995	Roy Curtiss	
	AS	US-5,451,499	09-19-1995	Mark D. Cochran	
	AT	US-5,453,364	09-26-1995	Enzo Paoletti	
	AU	US-5,462,734	10-31-1995	Geoffrey J. Letchworth	
	AV	US-5,470,734	11-28-1995	Paulus J. A. Sondermeijer	
	AW	US-5,482,713	01-09-1996	Enzo Paoletti	
	AX	US-5,580,859	12-03-1996	Philip L. Felgner	
	AY	US-5,593,972	01-14-1997	David B. Weiner	
	AZ	US-5,593,972	01-14-1997	David B. Weiner	
	BA	US-5,676,594	10-14-1997	Egbertus M. Joosten	
	BB	US-5,703,055	12-30-1997	Philip L. Felgner	
	BC	US-5,739,118	04-14-1998	Richard A. Carrano	
	BD	US-5,817,634	10-06-1998	Elias Meezan	
	BE	US-5,830,876	11-03-1998	David B. Weiner	
	BF	US-5,962,425	10-05-1999	Joseph A. Walder	
	BG	US-5,981,505	11-09-1999	David B. Weiner	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/560,653
Filing Date	November 20, 2006
First Named Inventor	David B. Weiner
Art Unit	1648
Examiner Name	Bao Q. Li
Attorney Docket Number	130694.02201

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BH	WO 94/016737	08-04-1994	Weiner		
	BI	WO 98/44129	10-08-1998	The Council of the Queensland Institute of Medical Research		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/560,653
		Filing Date	November 20, 2006
		First Named Inventor	David B. Weiner
		Art Unit	1648
		Examiner Name	Bao Q. Li
Sheet	3	of	4
		Attorney Docket Number	130694.02201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BJ	Chaudhary, V.K., et al., "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. USA</i> (1990) 87(3):1066-70.	
	BK	Chiu et al., "The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes," <i>Cell</i> (1988) 54(2):541-552.	
	BL	Durkop, H et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease," <i>Cell</i> (1992) 68(3):421-427.	
	BM	Franklin et al., "Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells," <i>Oncogene</i> (1995) 11(11):2365-74.	
	BN	Gilmore et al., "The I kappa B proteins: members of a multifunctional family," <i>Trends Genet</i> (1993) 9(12):427-33.	
	BO	Howell, M.D., et al., "Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis," <i>Proc. Nat. Acad. Sci USA</i> . (1991) 88:10921-10925.	
	BP	Lee et al., "Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements," <i>Cell</i> (1987) 49(6):741-752.	
	BQ	Meyer R., et al., "Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha," <i>Proc. Natl. Acad. Sci USA</i> (1991) 88(3):966-970.	
	BR	Oksenberg, J.R., et al., "Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients," <i>Nature</i> (1990) 345(6264):344-346.	
	BS	Paliard, X., et al., "Evidence for the effects of a superantigen in rheumatoid arthritis," <i>Science</i> (1991) 253(5017):325-329.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	10/560,653
Filing Date	November 20, 2006
First Named Inventor	David B. Weiner
Art Unit	1648
Examiner Name	Bao Q. Li
Attorney Docket Number	130694.02201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BT	Rauscher et al., "Fos-associated protein p39 is the product of the jun proto-oncogene," <i>Science</i> (1988) 240(4855):1010-1016.	
	BU	Smith, C.A., et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> (1993) 73(7):1349-1360.	
	BV	Williams, W.V., et al., "Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium," <i>J Clin. Invest.</i> (1992) 90(2):326-333.	
	BW	Wucherpfennig, K.W., et al., "Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein," <i>Science</i> (1990) 248(4958):1016-1019.	
	BY	Murakami, M. "High-level expression of exogenous genes by replication-competent retrovirus vectors with an internal ribosomal entry site." <i>Gene</i> (1997) 202:23-29.	
	BZ	Clement, A. et al., "Prime-boost immunization with DNA and modified vaccine virus Ankara vector expressing herpes simplex virus-2 glycoprotein d elicits create specific antibody and cytokine responses than DNA vaccine alone, 1000-1002. <del>J. Infectious Dis.</del> <b>J. Infectious Dis. 2001, Vol. 186, pages 1065-1073.</b>	
	CA	Luo, Y. et al., "Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine." <i>PNAS</i> (2003) 100; 8850-8855.	
			/B.L./ 04/21/2011

Examiner Signature	/Bao Li/	Date Considered	04/21/2011
-----------------------	----------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./